A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

Sponsor
Boehringer Ingelheim
Study ID
NCT07413913
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants' health. To assess the study endpoints, participants regularly have blood samples taken.

Key Dates

First listed
Feb 17, 2026
Start date
Mar 3, 2026
Status verified
Jun 2026
Primary completion
May 28, 2026
Completion
Jun 11, 2026

Study Design

Enrollment
56 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Survodutide formulation A then Survodutide formulation B2
    Survodutide formulation A = Reference treatment Survodutide formulation B2 = Test treatment
  • Experimental: Survodutide formulation B2 then Survodutide formulation A
    Survodutide formulation A = Reference treatment Survodutide formulation B2 = Test treatment

Primary Outcome Measure

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [ Time Frame: Up to Day 22 ]

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies